QVM149 clinical trials
Also written QVM149.
How each study uses QVM149 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the QVM149 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- QVM149
- 5
Studies by the year they started
5 studies that test it; most in 2017 (1)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 2
Novartis Pharmaceuticals (3) · University Medical Center Groningen (1) · Dr. Grace Parraga (1)
Studies
Open first, then newest update. How each study uses QVM149 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.RecruitingPhase 3Novartis PharmaceuticalsNCT05776927Written as QVM149
- Anti-inflammatory Effects GlycopyrroniumCompletedPhase 3University Medical Center GroningenNCT04259164Written as QVM149
- Investigating the Effects of QVM149 on MRI Ventilation DefectsWithdrawnPhase 3Dr. Grace ParragaNCT04206761Written as QVM149
- Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + TiotropiumCompletedPhase 3Novartis PharmaceuticalsNCT03158311Written as QVM149
- A Long-term Safety Study of QVM149 in Japanese Patients With AsthmaCompletedPhase 3Novartis PharmaceuticalsNCT03100825Written as QVM149